NCT04284995 - A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

November 8, 2020

Study Completion Date

December 14, 2020

Conditions

Coronary DiseaseMyocardial InfarctionHeart DiseasesVascular DiseasesSTEMI - ST Elevation Myocardial Infarction

Interventions

DRUG

RUC-4 Compound

All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.

Trial Locations (1)

3435

St. Antonius hospital, Nieuwegein